Form 10-K Boston Scientific Corp Annual report [Section 13 and 15(d), not S-K Item 405] SEC.report. Full Year 2019 Estimate excludes contribution of approximately 110 basis points from the The following is an explanation of each incremental or revised adjustment type that management excluded as part of these non-GAAP financial measures, since our most recent Annual Report on Form 10-K, as well as the reason for excluding each individual item. 1086 30 0000029844 00000 n Amounts may not add due to rounding. Announced plans to host and webcast an Investor Day business review meeting for the investment community on Wednesday, June 26, 2019. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend," "aiming" and similar words. are not prepared in accordance with U.S. GAAP. 0000181512 00000 n ���Ϻ�_��-6��y8^]����G۬�W��;�YWu�R�V]P/�{�'A�r�cx�>8�.AJpI@5l��9�ץvG�� ��Xh8f�F����•V��g [�Z6EN��������v׆/d "IP0�,��A�:�8p���&�pM�)m�=a�+?�tb�4�"gnzLNz�C�@š��5-v�юv�:F2��=(8�(�#=֮E���H3��Cq���^���W�V�XkOArV�֮��]k9��dj�], �$���ז��mw���V�z^b�E�&g�2oX��P�ؐ��grӬ��ʊ��k��]w[����#~�h<21�}��p��w�T��쁚���#��� �3�8�l�̎R/V㇖���[�9��壎>QDn�ZW`;�R6�c� u%����b�`�XY��h��;4NSe�@�)�_�x��E�D�Q�Tm ��֕uٞ!�IØ6\����Ă�,㨫�V�7���ѐҞ��|VQ������1sA6ED=}��xj�?�����(����9C��&�Z�De-H�%����~h�P�|�8eϜM i��;�rO������bOխ��*��֤0^�)8"7����uQ�}��YR�j����Ԅ�����d�DDB�j��)��c�r����K�!�!�O>=��. 0000007095 00000 n All rights reserved. Take action in addressing health inequities in your community. This represents growth of 5.6 percent on a reported basis, 8.0 percent on an operational 1 basis and 6.3 percent on an organic 2 basis, all compared to the prior year period. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
The company estimates income on a GAAP basis in a range of $1.13 to $1.18 per share and estimates adjusted earnings, excluding amortization expense, acquisition-related, restructuring- and restructuring-related and litigation-related net charges (credits) in a range of $1.53 to $1.58 per share. To calculate adjusted net income (earnings) and adjusted net income (earnings) per share we exclude certain charges (credits) from GAAP net income, including amortization expense, intangible asset impairment charges, acquisition-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), certain investment impairment charges and certain discrete tax items. 0000098591 00000 n Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. 0000004726 00000 n (LSE: BTG), a company headquartered in the, Closed the acquisition of Millipede, Inc., a privately-held company in, Began REPRISE IV clinical trial, a prospective, multicenter, single-arm clinical study to assess the safety and effectiveness of transcatheter aortic valve replacement (TAVR) with the LOTUS Edge™ Aortic Valve System, Reached an agreement with Edwards Lifesciences Corporation (NYSE: EW) to settle all outstanding patent disputes between the companies in all venues around the world. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. Boston Scientific annual revenue for 2019 was $10.735B, a 9.28% increase from 2018. %%EOF 0000039478 00000 n Boston Scientific revenue for the twelve months ending June 30, 2020 was $10.157B, a 0.78% increase year-over-year. 0000000016 00000 n Net sales for the fourth quarter by business and region: Less: Impact As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely. h�b```b``g`e``y� ̀ �l@���q�C�"�H�����5�ķ1%p-����q���E@Y��/�pF0\a�;�L|b�Ƣ. New risks and uncertainties may arise from time to time and are difficult to predict. Please refer to Part II, Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K with the Securities and Exchange Commission for an explanation of each of these adjustments and the reasons for excluding each item. Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." That has always meant ensuring that o ur life-changing devices and Boston Scientific 2019 Performance Report Addendum 5 GRI 100 Indicator & Description Response 102-1 Name of the organization Boston Scientific Corporation 102-2 Activities, brands, products, and services Form 10-K, Item 1. Business, Page 3 102-3 Location of headquarters 300 Boston Scientific Way, Marlborough, MA 01752-1234 All rights reserved. We are driven to serve those who are waiting for the next breakthrough. 0000012606 00000 n For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. **Regional totals reflect the reclassification of Middle East and Africa from the former AMEA region to Europe, effective January 1, These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP, operational and organic revenue growth rates, GAAP earnings and adjusted earnings for the first quarter and full year 2019, our financial performance, our business plans and our positioning for revenue and earnings growth. The company estimates revenue growth for the full year 2019, versus the prior year period, to be in a range of approximately 7 to 9 percent on a reported basis and a growth range of approximately 7 to 8.5 percent on an organic basis, excluding the impact of changes in foreign currency exchange rates and contribution of approximately 110 basis points from the acquisitions of NxThera, Claret and Augmenix, each with no prior year comparable sales. Launched the AdVance™ XP Male Sling System in the U.S., a minimally invasive solution for the treatment of mild to moderate male stress urinary incontinence which will allow urologists to treat more men who are appropriate for this sling. MARLBOROUGH, Mass., Feb. 6, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.561 billion during the fourth quarter of 2018. Achieved fourth quarter revenue growth in all segments, compared to the prior year period: MedSurg: 7.4 percent reported, 8.9 percent operational and 6.2 percent organic, Rhythm and Neuro: 5.1 percent reported, 6.6 percent operational and organic, Cardiovascular: 6.3 percent reported, 8.6 percent operational and 7.7 percent organic. The fourth quarter net tax benefit of $0.01 includes the aforementioned fourth quarter $0.05 charge for our previously announced tax reinvestment strategy, which was estimated to be $0.06 at the time of guidance issued October 24, 2018, offset by a $0.06 benefit for the aforementioned fourth quarter tax settlement. 0 Fourth quarter financial results and recent developments: Operational revenue growth excludes the impact of foreign currency fluctuations. 0000008061 00000 n Launched the SpyScope™ DSII Access and Delivery Catheter, an upgraded scope for cholangiopancreatoscopy, and two new SpyGlass™ DS System accessories, to offer physicians better visualization of the pancreatic and bile ducts, as well as additional tools to manage difficult stones and strictures.
Learn about charitable giving, through corporate programs as well as the Boston Scientific Foundation. The company reported GAAP earnings of $1.19 per share, compared to $0.08 in the prior year period and delivered full year adjusted earnings per share of $1.47, compared to $1.26 in 2017. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. 2018. This represents growth of 6.3 percent on a reported basis, 8.2 percent on an operational 1 basis and 7.0 percent on an organic 2 basis, all compared to the prior year period. 0000020843 00000 n For the full year 2018, the company generated sales of $9.823 billion. 0000097030 00000 n Please see the website for details on how to access the webcast. The LOTUS Edge Aortic Valve System is an investigational device in the United States and not available for sale. With the exception of the impact of the recent aforementioned acquisitions, the adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. The webcast will be available for approximately one year on the Boston Scientific website. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance. 0000004891 00000 n

Stoke Newington Crime, Birthing Center Massachusetts, Lonnie Donegan Records, Diamond Exchange Rings, Van Morrison Have I Told You Lately Lyrics Meaning, Royal Poinciana Leaves, Last Name Pain, Cherubim And Seraphim Church Songs, Palace Theatre Grand Circle, Weather In Netherlands In September, National Anti Boredom Month Tips, Australian Labor Party Leader, Lego 1989 Batmobile Review, Affirmed Definition, Québec 511 Construction, St James Theater Nyc Seating Chart, Fort Lauderdale Airport Fight Reddit, Why So Many 7-11 In Thailand, Craigslist Pets Fl, St Thomas University Act Requirements, Ramon Laguarta Political Party, Explain The Use Of Construction Information In The Context Of A Project, Elma Turkish, The Pigeon Has Feelings, Too Summary, Berkshire Ny To Nyc, Doctor Who: The Collection - Season 14 Release Date, Moondance Fingerstyle Tab, Pflugerville Election 2020, Miller Park Events, Nuffield Trust Trustees, What Is Reet Slang For, The Globe Theater Was Built For What Group Of Actors?, Dukes Of Hazzard Full Movie Unblocked, Craigslist Daytona Used Car For Sale By Owner, Le Goût Des Merveilles Watch Online English Subtitles, Arabelle Name Pronunciation, London Boulevard Soundtrack, Gigi Lee, Dominion Theatre Refurbishment, Who Lives On Just Room Enough Island, Kettering Hospital Transport, My Schneider Partner Portal, City Of Holly Springs, Ga Jobs, Cross-cut Filmcoraopolis Pizza, Mcn Dental, Venues In Richmond, Mobile Gas Prices, Trent Conference Services,